Clinuvel Pharmaceuticals Company Description

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).

The company’s pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.

It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism.

The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

Clinuvel Pharmaceuticals Limited

Country	Australia
Founded	1999
Industry	Biotechnology
Sector	Healthcare
Employees	16
CEO	Philippe Wolgen

Contact Details

Address: 535 Bourke Street Melbourne, 3000 Australia
Phone	61 3 9660 4900
Website	clinuvel.com

Stock Details

Ticker Symbol	CUV
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU000000CUV3
SIC Code	2836

Key Executives

Name	Position
Dr. Philippe Jacques Wolgen M.B.A., M.D.	Chief Executive Officer, MD and Director
Dr. Dennis J. Wright BPharm, M.Sc., Ph.D.	Chief Scientific Officer
Peter Vaughan	Chief Financial Officer
Lachlan Hay	Chief Operations Officer
Malcolm Bull	Head of Australian Operations and Investor Relations
Dr. Rose Quadbeck-Diel	Senior Vice President of Regulatory Affairs
Dr. Azza Hamila	Head of Quality Assurance and Drug Safety
Claire Newstead-Sinclair C.A.	Company Secretary